Elicera Therapeutics AB (OSTO:ELIC) ROE % Adjusted to Book Value : -62.41% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB ROE % Adjusted to Book Value?

Elicera Therapeutics AB's ROE % for the quarter that ended in Mar. 2024 was -99.86%. Elicera Therapeutics AB's PB Ratio for the quarter that ended in Mar. 2024 was 1.60. Elicera Therapeutics AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -62.41%.

Elicera Therapeutics AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Elicera Therapeutics AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB ROE % Adjusted to Book Value Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-22.11

-21.57

-9.37

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial													-12.18	-28.44	-31.58	-14.74	-62.41

Competitive Comparison of Elicera Therapeutics AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Elicera Therapeutics AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's ROE % Adjusted to Book Value falls into.

Elicera Therapeutics AB ROE % Adjusted to Book Value Calculation

Elicera Therapeutics AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-74.20%	/	7.92
	=	-9.37%

Elicera Therapeutics AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-99.86%	/	1.60
	=	-62.41%

Elicera Therapeutics AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines